TCM
ACAD icon

Tekla Capital Management’s Acadia Pharmaceuticals ACAD Stock Holding History

Tekla Capital Management’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-72,225
Closed -$1.15M – 178
2022
Q4 		$1.15M Hold
72,225
– – 0.04% 133
2022
Q3 		$1.18M Hold
72,225
– – 0.05% 129
2022
Q2 		$1.02M Hold
72,225
– – 0.04% 133
2022
Q1 		$1.75M Hold
72,225
– – 0.06% 129
2021
Q4 		$1.69M Buy
+72,225
New +$1.45M 0.05% 130
2021
Q3 		– Sell
-331,789
Closed -$8.09M – 173
2021
Q2 		$8.09M Hold
331,789
– – 0.26% 96
2021
Q1 		$8.56M Hold
331,789
– – 0.29% 90
2020
Q4 		$17.7M Buy
331,789
+81,046
+32% +$4.02M 0.62% 45
2020
Q3 		$10.3M Hold
250,743
– – 0.39% 60
2020
Q2 		$12.2M Buy
250,743
+29,144
+13% +$1.4M 0.46% 47
2020
Q1 		$9.36M Buy
221,599
+3,316
+2% +$137K 0.42% 45
2019
Q4 		$9.34M Buy
218,283
+58,136
+36% +$2.53M 0.35% 66
2019
Q3 		$5.76M Hold
160,147
– – 0.25% 76
2019
Q2 		$4.28M Buy
160,147
+55,433
+53% +$1.42M 0.17% 97
2019
Q1 		$2.81M Buy
+104,714
New +$2.45M 0.11% 119
2018
Q4 		– Sell
-93,689
Closed -$1.95M – 204
2018
Q3 		$1.95M Hold
93,689
– – 0.07% 157
2018
Q2 		$1.43M Hold
93,689
– – 0.05% 150
2018
Q1 		$2.1M Sell
93,689
-152,196
-62% -$4.21M 0.08% 133
2017
Q4 		$7.4M Buy
+245,885
New +$7.86M 0.29% 68
2017
Q1 		– Sell
-111,800
Closed -$3.22M – 140
2016
Q4 		$3.22M Hold
111,800
– – 0.14% 87
2016
Q3 		$3.56M Sell
111,800
-251,785
-69% -$8.54M 0.14% 98
2016
Q2 		$11.8M Sell
363,585
-351,714
-49% -$11.8M 0.48% 53
2016
Q1 		$20M Buy
715,299
+77,799
+12% +$1.7M 0.85% 30
2015
Q4 		$22.7M Buy
637,500
+75,000
+13% +$2.64M 0.82% 24
2015
Q3 		$18.6M Buy
562,500
+192,500
+52% +$8.01M 0.67% 33
2015
Q2 		$15.5M Buy
+370,000
New +$14.3M 0.56% 39

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Tekla Capital Management's ACAD Position: Q1 2023 in Review

Tekla Capital Management sold out of Acadia Pharmaceuticals (ACAD) in Q1 2023, closing a stake of 72,225 shares — an estimated $1.15M sold.

Tekla Capital Management first reported a position in ACAD in Q2 2015 and held it in 26 quarters. The position peaked at $22.7M in Q4 2015. 233 funds tracked by Wall St. Rank hold ACAD as of Q1 2023.

  • Tekla Capital Management reported no remaining Acadia Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • Tekla Capital Management sold 72,225 Acadia Pharmaceuticals shares in Q1 2023, an estimated $1.15M.
  • Tekla Capital Management first reported a position in Acadia Pharmaceuticals in Q2 2015 and held it in 26 quarters.
  • Tekla Capital Management's Acadia Pharmaceuticals position peaked at $22.7M in Q4 2015.
  • 233 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2023.

Based on Tekla Capital Management's 13F filing for Q1 2023, filed 10 May 2023.